ELVN News
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearPR NewswireBURLINGAME, Calif., Oct. 14, 2026Accomplished...
PR Newswire
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearPR NewswireBURLINGAME, Calif., Oct. 14, 2026Accomplished...
PR Newswire
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid...
PR Newswire
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.read more...
Benzinga
Enliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics to Present at Upcoming Investor Conferences Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire BURLINGAME, Calif., Sept. 3, 2026 BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a...
PR Newswire
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting PR Newswire BURLINGAME, Calif., Aug. 31, 2026...
PR Newswire
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.read more...
Benzinga
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update PR Newswire BURLINGAME, Calif., Aug. 5, 2026 Announced positive Phase 1 clinical data for ELVN-001 in CML...
PR Newswire
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
Key PointsA director of Enliven Therapeutics reported selling 10,000 shares in open-market transactions on June 5, 2026, for a total value of $345,000...
Nasdaq News: Markets
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally...
Yahoo! Finance: News
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full...
PR Newswire